Document Detail


Creating genetic resistance to HIV.
MedLine Citation:
PMID:  22985479     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
HIV/AIDS remains a chronic and incurable disease, in spite of the notable successes of combination antiretroviral therapy. Gene therapy offers the prospect of creating genetic resistance to HIV that supplants the need for antiviral drugs. In sight of this goal, a variety of anti-HIV genes have reached clinical testing, including gene-editing enzymes, protein-based inhibitors, and RNA-based therapeutics. Combinations of therapeutic genes against viral and host targets are designed to improve the overall antiviral potency and reduce the likelihood of viral resistance. In cell-based therapies, therapeutic genes are expressed in gene modified T lymphocytes or in hematopoietic stem cells that generate an HIV-resistant immune system. Such strategies must promote the selective proliferation of the transplanted cells and the prolonged expression of therapeutic genes. This review focuses on the current advances and limitations in genetic therapies against HIV, including the status of several recent and ongoing clinical studies.
Authors:
John C Burnett; John A Zaia; John J Rossi
Related Documents :
3112489 - Possible infectious causes in 651 patients with acute viral hepatitis during a 10-year ...
24134179 - Identification of host and viral factors involved in a dissimilar resolution of a hepat...
23555249 - Lymphotoxin signaling is initiated by the viral polymerase in hcv-linked tumorigenesis.
23199719 - Predictors of mortality among hiv-infected patients initiating anti retroviral therapy ...
23563519 - Eliminating the latent hiv reservoir by reactivation strategies: advancing to clinical ...
23121249 - Influence of episodes of intermittent viremia ("blips") on immune responses and viral l...
14629329 - Hepatitis c virus infection in thai patients with oral lichen planus.
23721009 - Liver transplantation in the meld era--analysis of the optn/unos registry.
1734399 - Thymic abnormalities in fetuses aborted from human immunodeficiency virus type 1 seropo...
Publication Detail:
Type:  Journal Article; Review     Date:  2012-09-15
Journal Detail:
Title:  Current opinion in immunology     Volume:  24     ISSN:  1879-0372     ISO Abbreviation:  Curr. Opin. Immunol.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-22     Completed Date:  2013-01-22     Revised Date:  2013-10-17    
Medline Journal Info:
Nlm Unique ID:  8900118     Medline TA:  Curr Opin Immunol     Country:  England    
Other Details:
Languages:  eng     Pagination:  625-32     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Ltd. All rights reserved.
Affiliation:
Beckman Research Institute of the City of Hope, Duarte, CA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acquired Immunodeficiency Syndrome / drug therapy,  genetics,  immunology
Anti-HIV Agents / economics,  therapeutic use
Anti-Retroviral Agents / economics,  therapeutic use*
Clinical Trials as Topic
Drug Resistance, Viral / genetics*,  immunology
Genetic Therapy / economics,  methods*
HIV-1 / drug effects,  genetics*,  immunology
Humans
Grant Support
ID/Acronym/Agency:
R01 AI029329/AI/NIAID NIH HHS; R01 AI042552/AI/NIAID NIH HHS; R01 HL074704/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/Anti-Retroviral Agents
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The Prehospital assessment of severe trauma patients` performed by the specialist ambulance nurse in...
Next Document:  Type 2 innate lymphoid cells: new players in asthma and allergy.